Search      Current Studies    April 17, 2014  
MEMBER LOGIN


Forgot Password ?
CUTANEOUS LYMPHOMA CLINICAL TRIALS: Minimize


List of Active Recruiting Clinical Trials for Cutaneous Lymphoma in United States

1.     Study of Oral LBH589 in Adult Patients with Refractory Cutaneous T-cell Lymphoma

ClinicalTrials.gov Identifier: NCT00425555

Purpose: This study will evaluate the safety and efficacy of LBH489B in adult patients with refractory Cutaneous T-Cell Lymphoma.

Condition: Cutaneous T-cell Lymphoma

Intervention: LBH5899, histone deacetylase (HDAC) inhibitor

Phase: II & III

Sponsor: Novartis

2.     Study of Oral LBH589 in Adult Patients with Refractory Cutaneous T-cell Lymphoma-2212

ClinicalTrials.gov Identifier: NCT00490776

Purpose: This study will evaluate the safety and efficacy of LBH489B in adult patients with refractory Cutaneous T-Cell Lymphoma and prior HDAC inhibitor therapy

Condition: Cutaneous T-cell Lymphoma

Intervention: LBH5899, histone deacetylase (HDAC) inhibitor

Phase: II & III

Sponsor: Novartis

3.     FR901228 in Treating Patients with T-cell Lymphoma

ClinicalTrials.gov Identifier: NCT00020436

Purpose: This phase II trial will evaluate the safety and efficacy of FR901228 (romidepsin) in treating patients with T-cell lymphoma.

Condition: Lymphoma

Intervention: FR901228 (Romidepsin), histone deacetylase (HDAC) inhibitor

Phase: II

Sponsor: National Cancer Institute (NCI)

4.     Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-cell Lymphoma, Mycosis Fungoides) Stage IA, IB, IIA

ClinicalTrials.gov Identifier: NCT00221039

Purpose: The study objective is to demonstrate that UVADEX® Sterile Solution formulation of methoxsalen used in conjunction with the UVAR XTS Photopheresis System can have a clinical effect on the skin manifestations of CTCL (mycosis fungoides) in early stage disease.

Condition: Cutaneous T-cell Lymphoma (mycosis fungoides)

Intervention: UVADEX (methoxsalen) Solution with UVAR XTS Photopheresis

Phase: IV

Sponsor: Therakos

5.     Immunization Against Tumor Cells in Sézary Syndrome

ClinicalTrials.gov Identifier: NCT00099593

Purpose: This research is being done to look at the safety and immune responses due to a dendritic cell (DCs) vaccine in patients with cutaneous T-cell lymphoma (CTCL) and Sézary Syndrome. Condition: Cutaneous T-cell Lymphoma, Sézary Syndrome

Intervention: Biological (Autologous Dendritic Cell Vaccine)

Phase: II

Sponsor: University of Pittsburgh Department of Dermatology

6.     A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma

ClinicalTrials.gov Identifier: NCT00431912

Purpose: This phase II study is designed to determine the efficacy and safety of APO866 for the treatment of patients with advanced forms of cutaneous T-cell lymphoma (CTCL). Condition: Cutaneous T-cell Lymphoma

Intervention: APO866 (induces cell death by specifically inhibiting the biosynthesis of NAD+ from niacinamide)

Phase: II

Sponsor: Apoxis SA

7.     Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sézary Syndrome

ClinicalTrials.gov Identifier: NCT00127881

Purpose: The purpose of this study is to determine the efficacy of the drug, HuMax-CD4, in patients with mycosis fungoides (MF) and Sézary syndrome who are intolerant to or do not respond to treatment with Targretin® (Bexarotene) and one other standard therapy.

Condition: Mycosis Fungoides, Sézary Syndrome

Intervention: HuMax-CD4 (zanolimumab), (monoclonal antibody against-CD4)

Phase: III

Sponsor: Genmab

8.     Study of Pralatrexate in Patients with Relapsed of Refractory Cutaneous T-cell Lymphoma

ClinicalTrials.gov Identifier: NCT00554827

Purpose: This phase I study is designed to determine an effective and well-tolerated dose and schedule of pralatrexate when administered concurrently with vitamin B12 and folic acid supplementation to patients with relapsed or refractory CTCL.

Condition: Relapsed or refractory cutaneous T-cell lymphoma

Intervention: (RS)-10-Propargyl-10-Deazaaminopterin (pralatrexate)

Phase: I

Sponsor: Allos Therapeutics

9.     Clinical Trial of PXD101 in Patients with T-cell Lymphomas

ClinicalTrials.gov Identifier: NCT00274651

Purpose: This trial will assess the effectiveness of PXD101 in patients with recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas.

Condition: Cutaneous T-cell lymphoma, peripheral T-cell lymphoma, Non-Hodgkin’s lymphoma

Intervention: Belinostat (PXD101), histone deacetylase (HDAC) inhibitor

Phase: II

Sponsor: CuraGen Corporation, Topo Target A/S

10.  Single Agent Phase II Study of Forodesine (BCX1777) in the Treatment of Cutaneous T-cell Lymphoma

ClinicalTrials.gov Identifier: NCT00501735

Purpose: This study is designed to assess objective response in subjects with cutaneous manifestations of CTCL with stage IIB, III, and IVA CTCL. Additionally, this study will evaluate the safety and tolerability of CTCL subjects Stages IB, IIA, III, or IVA treated with oral forodesine.

Condition: T-cell lymphoma

Intervention: Forodesine (BCX1777), inhibitor of purine nucleoside phosphorylase

Phase: II

Sponsor: BioCryst Pharmaceuticals

11.  Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides

ClinicalTrials.gov Identifier: NCT00168064

Purpose: This study will evaluate the efficacy, tolerability and safety of the topical application of nitrogen mustard (NM) ointment formulations in patients with stage IA or IIA MF.

Condition: Mycosis fungoides

Intervention: Nitrogen mustard

Phase: II

Sponsor: Yaupon Therapeutics

12.  Topical Romidepsin in Treating Patients with Stage I or Stage II Cutaneous T-cell Non-Hodgkin’s Lymphoma

ClinicalTrials.gov Identifier: NCT00477698

Purpose: This phase I trial is studying the side effects and best dose of topical romidepsin in treating patients with stage I or stage II cutaneous T-cell Lymphoma.

Condition: Lymphoma

Intervention: Romidepsin, histone deacetylase (HDAC) inhibitor

Phase: I

Sponsor: National Cancer Institute (NCI)

13.  Liposomal Doxorubicin Followed by Bexarotene in Treating Patients with Cutaneous T-cell Lymphoma

ClinicalTrials.gov Identifier: NCT00255801

Purpose: This phase II trial is studying how well giving liposomal doxorubicin followed by bexarotene works in treating patients with cutaneous T-cell lymphoma.

Condition: Lymphoma

Intervention: Bexarotene and pegylated liposomal doxorubicin hydrochloride

Phase: II

Sponsor: National Cancer Institute (NCI), Memorial Sloan-Kettering Cancer Center

14.  LMB-2 lmmunotoxin in Treating Patients with CD25+ Cutaneous T-cell Lymphoma

ClinicalTrials.gov Identifier: NCT00085085

Purpose: This phase II trial is studying how well LMB-2 immunotoxin works in treating patients with cutaneous T-cell lymphoma.

Condition: Lymphoma

Intervention: Anti-Tac(Fv)-PE38 (LMB-2) immunotoxin, antibody-drug conjugate therapy
Phase: II

Sponsor: National Cancer Institute (NCI)

15.  Gemcitabine and Pemetrexed Disodium in Treating Patients with Advanced Mycosis Fungoides or Sézary Syndrome

ClinicalTrials.gov Identifier: NCT00369629

Purpose: This phase I/ II trial is studying the side effects and best dose of gemcitabine hydrochloride when given together with pemetrexed disodium and to see how well they work in treating patients with advanced mycosis fungoides or Sézary syndrome. 

Condition: Lymphoma

Intervention: Gemcitabine hydrochloride and pemetrexed disodium

Phase: I & II

Sponsor: National Cancer Institute (NCI), Robert H. Lurie Cancer Center

16.  Lenalidomide in Treating Patients with Relapsed Mycosis Fungoides/ Sézary Syndrome

ClinicalTrials.gov Identifier: NCT00466921

Purpose: This phase II trial is studying how well lenalidomide works in treating patients with relapsed mycosis fungoides/ Sézary syndrome. 

Condition: Lymphoma

Intervention: CC-5013 (Lenalidomide, Revlimid®)

Phase: II

Sponsor: National Cancer Institute (NCI), Robert H. Lurie Cancer Center

17.  Alemtuzumab in Treating Patients with Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome

ClinicalTrials.gov Identifier: NCT00057967

Purpose: This phase II trial is studying how well alemtuzumab works in treating patients with relapsed or refractory advanced mycosis fungoides or Sézary syndrome.  

Condition: Lymphoma

Intervention: alemtuzumab, anti-CD52 monoclonal antibody

Phase: II

Sponsor: National Cancer Institute (NCI), Robert H. Lurie Cancer Center

18.  Bortezomib in Treating Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma

ClinicalTrials.gov Identifier: NCT00182637

Purpose: This phase II trial is studying how well bortezomib works in treating patients with relapsed or refractory cutaneous T-cell lymphoma.

Condition: Lymphoma

Intervention: Bortezomib (VELCADE®)

Phase: II

Sponsor: National Cancer Institute (NCI), Jonsson Comprehensive Cancer Center

19.  Allogeneic Transplantation in Patients with Cutaneous T-cell Lymphoma

ClinicalTrials.gov Identifier: NCT00506129

Purpose: To assess the toxicity of allogenic peripheral blood progenitor cell (PBPC) or marrow transplantation in patients with cutaneous T-cell lymphoma. To determine the patient’s response, long term overall survival and disease-free survival (DFS). To determine whether a graft vs CTCL can occur.

Condition: Lymphoma

Intervention: Fludarabine and melphalan

Phase: II

Sponsor: M.D. Anderson Cancer Center

20.  LAAMP Trial for Peripheral and Cutaneous T-cell Lymphoma

ClinicalTrials.gov Identifier: NCT00161239

Purpose: In this study, four chemotherapeutic agents (L-asparaginase, methotrexate, doxil, and prednisone) will be administered in a combination regimen for patients with relapsed or refractory peripheral and/or advanced cutaneous T-cell lymphoma. Each one of these individual drugs have been shown to have activity to lymphomas. The objective of the study is to determine if the combination of these chemotherapy agents results in higher response and cure rates in this patient population.

Conditions: Lymphoma, Cutaneous T-cell lymphoma

Intervention: L-asparaginase, doxorubicin, methotrexate, and prednisone

Phase: This is a single institutional study which will include 32 patients with peripheral T-cell lymphoma and 32 patients in the cutaneous T-cell lymphoma

Sponsor: University of Medicine and Dentistry New Jersey, Ortho Biotech Products, L.P.

21.  Alefacept in Treating Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma or Peripheral T-cell Non-Hodgkin’s Lymphoma

ClinicalTrials.gov Identifier: NCT00438802

Purpose: This phase I trial is studying the side effects and best dose of alefacept in treating patients with relapsed or refractory cutaneous T-cell lymphoma or peripheral T-cell Non-Hodgkin’s Lymphoma

Condition: Lymphoma

Intervention: Alefacept (dimeric fusion protein of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1.

Phase: I

Sponsor: National Cancer Institute (NCI), Mayo Clinic

22.  A Randomized Phase II Study of Oral Sapacitabine in Patients with Advanced Cutaneous T-cell Lymphoma

ClinicalTrials.gov Identifier: NCT00476554

Purpose: This study is designed to evaluate the tolerability and response rate of high-dose and low-dose regimens in patients with advanced cutaneous T-cell lymphoma (CTCL) who have had progressive, recurrent, or persistent disease on or following 2 systemic therapies.

Condition: Cutaneous T-cell lymphoma

Intervention: Sapacitabine and its major metabolite, CNDAC, are oral nucleoside analogs that interfere with DNA synthesis by causing single-strand DNA breaks and induce arrest of the cell division cycle at G2 phase.

Phase: II

Sponsor: Cyclacel Pharmaceuticals, Inc.

23.  T-cell Repertoire Analysis of Immune Mediated Skin Diseases

ClinicalTrials.gov Identifier: NCT00368784

Purpose: This study is designed to identify the cells of the immune system that cause skin disease such as psoriasis and mycosis fungoides. Blood samples from many patients will be compared in hopes of finding common cells and molecules responsible for skin diseases. Results of this study will increase our knowledge about immune mediated skin disease.

Condition: Mycosis fungoides and psoriasis

Intervention: Blood withdrawal

Phase: III

Sponsor: University of California, Davis

24.  A-dmDT390-bisFv (UCHT1) Immunotoxin Therapy for Patients with T-cell Diseases

ClinicalTrials.gov Identifier: NCT00611208

Purpose: Objectives are, to determine how much of the drug can be given to an individual and what are the toxicities associated with the dru.g This is a Phase I/II clinical trial aimed at treating patients with T-cell lymphomas

Condition: Mycosis fungoides, Sézary syndrome, T-cell lymphomas, T-cell leukemia

Intervention: A-dmDT390-bisFv (UCHT1), antibody tagged with diphtheria toxin targeting CD3ε surface membrane protein

Phase: I/II

Sponsor: Scott and White Hospital and Clinic, National Institute of Mental Health (NIMH)

25.  Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Conditions

ClinicalTrials.gov Identifier: NCT00129415

Purpose: The purpose of this investigation is to study the effectiveness of longer wavelength UVA1 (340-400 nm) or shorter wavelength ultraviolet B [UVB] (290-320 nm) irradiation in the treatment of inflammatory skin conditions (such as atopic dermatitis, psoriasis, mycosis fungoides, alopecia areata, stretch marks and urticaria).

Condition: Mycosis fungoides, atopic dermatitis, alopecia, psoriasis, urticaria

Intervention: UVA1 and UVB irradiation

Phase: I/II

Sponsor: University of Michigan

26.  Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients with Actinic Keratosis, Bowen’s Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides

ClinicalTrials.gov Identifier: NCT00103246

Purpose: This phase I trial is studying the side effects and best dose of photodynamic therapy using silicon phthalocyanine 4 in treating patients with actinic keratosis, Bowen’s disease, skin cancer, or stage I or stage II mycosis fungoides.

Condition: Lymphoma, non-melanomatous skin cancer, precancerous/nonmalignant condition

Intervention: silicon phthalocyanine 4

Phase: I

Sponsor: Case Comprehensive Cancer Center,

27.  Alemtuzumab Followed by Peripheral Stem Cell Transplantation in Treating Patients with Advanced Mycosis Fungoides/ Sézary Syndrome

ClinicalTrials.gov Identifier: NCT00047060

Purpose: This phase I/II trial is studying how well giving alemtuzumab together with chemotherapy and donor peripheral stem cell transplantation works in treating patients with advanced mycosis fungoides and/or Sézary syndrome.

Condition: Lymphoma

Intervention: Alemtuzumab, cyclophosphamide, cyclosporine, fludarabine phosphate, and therapeutic allogeneic lymphocytes

Phase: I/II

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

28.  Effect of Denileukin Diftitox on Immune System in CTCL Patients

ClinicalTrials.gov Identifier: NCT00254332

Purpose: This is a blood and tissue study to determine the effect of denileukin diftitox on the immune system cells that may be involved in patient response to their cutaneous T-cell lymphoma. Condition: Cutaneous T-cell Lymphoma, Sézary Syndrome, Mycosis Fungoides

Intervention: denileukin diftitox (ONTAK®)

Phase: N/A

Sponsor: University of Pittsburgh Department of Dermatology

29.  Blood and Tissue Collection for Cutaneous Lymphoma Research

ClinicalTrials.gov Identifier: NCT00177268

Purpose: This is a tissue and blood banking protocol for cutaneous T-cell lymphoma (CTCL) patients for current and future CTCL research.

Condition: Cutaneous T-cell Lymphoma, Sézary Syndrome, Mycosis Fungoides

Intervention: Blood draw or skin biopsy

Phase: NA

Sponsor: University of Pittsburgh Department of Dermatology

30.  Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients with Cutaneous T-cell Lymphoma

ClinicalTrials.gov Identifier: NCT00430053

Purpose: This natural history study is collecting disease-related health information over time from patients with cutaneous T-cell lymphoma.

Condition: Lymphoma

Intervention: Procedures including biopsy, flow cytometry, gene rearrangement analysis, immunohistochemistry staining method, polymerase chain reaction, and proteonomic profiling.

Phase: NA

Sponsor: National Cancer Institute (NCI)

31.  Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma

ClinicalTrials.gov Identifier: NCT00419367

Purpose: This study will provide vorinostat to advanced cutaneous T-cell lymphoma patients who have no other treatment options for their disease (South America). Safety and efficacy will be evaluated.

Condition: Cutaneous T-cell Lymphoma

Intervention: Vorinostat

Phase: NA

Sponsor: Merck

32.  Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-Cell Lymphoma

ClinicalTrials.gov Identifier: NCT00394693

Purpose: The primary objective of this study is to evaluate the efficacy of a four-month dosing period of intra-lesional injection of TG1042 in patients with relapsing CBCL.

Condition: Cutaneous B-cell Lymphoma

Intervention: Genetic: an adenoviral vector construct containing the human interferon gamma gene (TG1042).

Phase: II

Sponsor: Transgene

33.  Radiolabeled Monoclonal Antibody Therapy in Treating Adult Patients Who Have Recurrent Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

ClinicalTrials.gov Identifier: NCT00019305

Condition: Lymphoma, including CTCL (Tac-Expressing Malignancies)

Purpose: This phase I/II trial is studying the side effects and best dose of radiolabeled monoclonal antibody when given together with pentetic acid calcium and to see how well they work in treating patients with recurrent Hodgkin's lymphoma or non-Hodgkin's lymphoma.

Interventions: Yttrium-90 (90-Y)-Radiolabeled Humanized Anti-Tac monoclonal antibody (daclizumab) and Calcium-DTPA (pentetic acid calcium); radio-immunotherapy; radioprotection

Phase: I/II

Sponsor: National Cancer Institute

34.  Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

ClinicalTrials.gov Identifier: NCT00345865

Condition: Lymphoma, including CTCL

Purpose: This phase II trial is studying how well autologous peripheral stem cell transplant works in treating patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.

Intervention: carboplatin;   carmustine;   cyclophosphamide;   etoposide;   filgrastim;   ifosfamide;   rituximab. Autologous hematopoietic stem cell transplantation;   total-body irradiation.

Phase: II

Sponsor: National Cancer Institute, University of Minnesota

     

  Copyright 2014 by ISCL   Terms Of Use  Privacy Statement